Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
Inés González-SuarezLuis Rodríguez de AntonioAida OrvizSara Moreno-GarcíaMaría D Valle-ArcosJordi A Matias-GuiuCristina ValenciaManuela Jorquera MoyaCelia Oreja-GuevaraPublished in: Brain and behavior (2017)
Discontinuation of NTZ treatment may trigger a severe rebound with marked clinical and radiological worsening. A very careful evaluation of benefit-risk should be considered before NTZ withdrawal, and a close monitoring and a short washout period is recommended after drug withdrawal.